ArticlePloS one2026
Evaluation of the effects of indocyanine green administration dose and speed on blood concentration and fluorescence in thoracoscopic segmentectomy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous administration of indocyanine green (ICG) is commonly used for visualizing lungs along the intersegmental plane; however, its effectiveness can be limited, as poor fluorescence sometimes leads to suboptimal structural delineation. We aimed to evaluate the effects of ICG dose and injection speed on blood concentration and fluorescence intensity during thoracoscopic segmentectomy. This was a two-stage, single-center study involving 30 patients who underwent segmentectomy. In the first stage, the administration rate was fixed at 300 mL/h and the dose was investigated at 0.1 mg/kg (group L) and 0.2 mg/kg (group H). In the second stage, a rate of 900 mL/h (group F) was added to the dose determined in the first stage and the relationship between the dose, administration rate, and fluorescence was investigated. During the first stage, the blood concentration of ICG at the end of the marking was higher in group H; hence, the dose in group F was set to 0.2 mg/kg. In the subsequent analysis, evaluation was performed by comparing the three groups. The maximum blood concentration of ICG was significantly higher in group F (9.5 mg/L, p < 0.01) than in the other groups. There was no difference in the fluorescence intensity between the groups. The fluorescence intensity of group L at the end of the marking was low (123.4, p = 0.03). The intersegment plane was confirmed in all cases, and there was no difference in the marking rate between the groups. Although injection speed affected blood ICG concentration, it did not significantly enhance fluorescence intensity. The administered dose of ICG determined the duration of fluorescence. Results suggest a minimum ICG dose is required to sustain fluorescence, while excessively rapid injections may cause early threshold attainment. Clinically, maintaining blood ICG concentration within the 5-10 mg/L is best achieved with a relatively slow infusion rate of 300 mL/h. Clinical trial registry number: UMIN-CTR No UMIN000047255.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.